Cargando…

Novel therapies in thrombotic thrombocytopenic purpura

ESSENTIALS: The standard of care for patients with TTP remains daily plasma exchange in addition to immune suppressive therapy. Despite the improved treatment options for TTP, the acute mortality of TTP remains between 15‐20%. Caplacizumab reduces the time to platelet recovery and the exacerbation r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masias, Camila, Cataland, Spero R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	State of the Art Isth 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055500/ https://www.ncbi.nlm.nih.gov/pubmed/30046703 http://dx.doi.org/10.1002/rth2.12066

Ejemplares similares

Prevention and treatment of the post‐thrombotic syndrome
por: ten Cate‐Hoek, Arina J.
Publicado: (2018)

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
por: Sukumar, Senthil, et al.
Publicado: (2021)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Platelets at the vascular interface
por: Bergmeier, Wolfgang, et al.
Publicado: (2017)

ISTH 2017 Berlin revisited
por: Ruf, Wolfram
Publicado: (2017)

Product type and other environmental risk factors for inhibitor development in severe hemophilia A
por: Peyvandi, Flora, et al.
Publicado: (2018)

Current and future burden of venous thrombosis: Not simply predictable
por: Scheres, Luuk J. J., et al.
Publicado: (2018)

Proteolytic processing of platelet receptors
por: Gardiner, Elizabeth E.
Publicado: (2018)

The coagulation system in atherothrombosis: Implications for new therapeutic strategies
por: Olie, Renske H., et al.
Publicado: (2018)

Glycoprotein VI in securing vascular integrity in inflamed vessels
por: Boulaftali, Yacine, et al.
Publicado: (2018)

Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination
por: Deucher, William, et al.
Publicado: (2022)

Illustrated State‐of‐the‐Art Capsules of the ISTH 2020 Congress
por: Ariens, Robert, et al.
Publicado: (2020)

Impact of novel hemophilia therapies around the world
por: Ozelo, Margareth C., et al.
Publicado: (2022)

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022)

Phosphatidylinositol 3‐monophosphate: A novel actor in thrombopoiesis and thrombosis
por: Valet, Colin, et al.
Publicado: (2020)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
por: Shima, Midori
Publicado: (2020)

The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy
por: Singh, Pradeep K., et al.
Publicado: (2021)

Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting
por: Kozieł, Monika, et al.
Publicado: (2020)

Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease
por: den Exter, Paul L., et al.
Publicado: (2022)

Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective
por: Kelley, Rachel A., et al.
Publicado: (2022)

What’s new in VTE risk and prevention in orthopedic surgery
por: Kahn, Susan R., et al.
Publicado: (2020)

Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018)

Hematologic concerns in extracorporeal membrane oxygenation
por: Sniderman, Jonathan, et al.
Publicado: (2020)

Platelet CLEC‐2 and lung development
por: Suzuki‐Inoue, Katsue, et al.
Publicado: (2020)

Plasminogen activation in the musculoskeletal acute phase response: Injury, repair, and disease
por: Gibson, Breanne H.Y., et al.
Publicado: (2020)

Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020)

VTE risk assessment in pregnancy
por: Ewins, Karl, et al.
Publicado: (2019)

Visualizing thrombosis to improve thrombus resolution
por: Weisel, John W., et al.
Publicado: (2021)

The role of platelets in sepsis
por: Shannon, Oonagh
Publicado: (2020)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

The von Willebrand factor – ADAMTS‐13 axis in malaria
por: O’Donnell, Andrew S., et al.
Publicado: (2022)

Disparities in obstetric hemorrhage outcomes
por: James, Andra H., et al.
Publicado: (2022)

Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
por: Barbui, Tiziano, et al.
Publicado: (2022)

Platelet‐leukocyte interactions in COVID‐19: Contributions to hypercoagulability, inflammation, and disease severity
por: Hottz, Eugenio D., et al.
Publicado: (2022)

Proteomics in thrombosis research
por: Edfors, Fredrik, et al.
Publicado: (2022)

Sialic acid and platelet count regulation: Implications in immune thrombocytopenia
por: Lee‐Sundlov, Melissa M., et al.
Publicado: (2022)

Reproductive issues in women on direct oral anticoagulants
por: Beyer‐Westendorf, Jan, et al.
Publicado: (2021)

GPIbα is the driving force of hepatic thrombopoietin generation
por: Karakas, Danielle, et al.
Publicado: (2021)

Fibrinolysis and bleeding of unknown cause
por: Mehic, Dino, et al.
Publicado: (2021)

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
por: Mavromanoli, Anna C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l0sbrf04hphbb4r3jpp3670598